Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair upped their FY2018 earnings per share estimates for shares of Hologic in a research note issued on Thursday. William Blair analyst B. Weinstein now anticipates that the medical equipment provider will post earnings per share of $2.23 for the year, up from their previous estimate of $2.12. William Blair also issued estimates for Hologic’s FY2019 earnings at $2.49 EPS.
HOLX has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. Deutsche Bank lowered Hologic from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research report on Friday, January 19th. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Cowen upgraded Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, December 20th. Finally, Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $48.36.
Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.05. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 EPS.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Grove Bank & Trust grew its position in Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares during the last quarter. Hall Laurie J Trustee grew its position in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in Hologic during the 2nd quarter worth approximately $191,000. NuWave Investment Management LLC bought a new position in Hologic during the 4th quarter worth approximately $199,000. Finally, National Asset Management Inc. bought a new position in Hologic during the 2nd quarter worth approximately $203,000. Institutional investors and hedge funds own 93.84% of the company’s stock.
In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.88% of the stock is currently owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.